Drug intelligence / Profile preview

DS-1205c + osimertinib

Development stage: Unknown
Lead developer: Nuvation Bio
Modality: Small Molecules
Administration: Oral

Overview

DS-1205c + osimertinib is a combination therapy consisting of DS-1205c, a novel, specific, small-molecule AXL receptor tyrosine kinase inhibitor, and osimertinib, an EGFR tyrosine kinase inhibitor. This combination was developed to address resistance to EGFR TKIs in non-small cell lung cancer. DS-1205c works by inhibiting the AXL receptor, which has been implicated in resistance mechanisms to EGFR TKIs, potentially restoring sensitivity to these agents in tumors that have developed resistance.

Targets

AXL (AXL receptor tyrosine kinase)

Beyond the preview

Go deeper on DS-1205c + osimertinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DS-1205c + osimertinib.

Explore the full profile